Given that 90% of HNSCC patients possess high epithelium growth factor receptor (EGFR) expression, cetuximab, a monoclonal antibody targeting EGFR, was approved for use in HNSCC patients to improve the response rate [3–6]. This evidence concerns the gene EGFR and head and neck squamous cell carcinoma.